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2ABSTRACT 1
2
A family of restriction enzyme- and ligation-independent cloning vectors has been 3
developed for producing recombinant His-tagged fusion proteins in Escherichia coli. These 4
are based on pURI2 and pURI3 expression vectors which have been previously used for the 5
successful production of recombinant proteins at the milligram scale. The newly designed 6
vectors combines two different promoters (lpp
p
-5 and T7 RNA polymerase Ø10), two 7
different endoprotease recognition sites for the His6-tag removal (enterokinase and tobacco 8
etch virus), different antibiotic selectable markers (ampicillin and erythromycin resistance), 9
and different placements of the His6-tag (N-and C-terminus). A single gene can be cloned 10
and further expressed in the eight pURI vectors by using six nucleotide primers, avoiding 11
the restriction enzyme and ligation steps. A unique NotI site was introduced to facilitate the 12
selection of the recombinant plasmid. As a case study, the new vectors have been used to 13
clone the gene coding for the phenolic acid decarboxylase from Lactobacillus plantarum. 14
Interestingly, the obtained results revealed markedly different production levels of the 15
target protein, emphasizing the relevance of the cloning strategy on soluble protein 16
production yield. Efficient purification and tag removal steps showed that the affinity tag 17
and the protease cleavage sites functioned properly. The novel family of pURI vectors 18
designed for parallel cloning is a useful and versatile tool for the production and 19
purification of a protein of interest.20
21
3Introduction 1
2
In many disciplines of protein research the use of recombinant proteins has 3
increased greatly in recent years. Bacterial expression systems for heterologous protein 4
production are attractive because of their ability to grow rapidly and at high density, low 5
cost, and high productivity [1]. The efficient large-scale production of disparate pure and 6
active recombinant proteins from different biological sources entails the optimization and 7
standardization of several steps, namely, cloning and overexpression of the target gene, 8
production of the soluble recombinant protein, purification, and (optionally) tag removal 9
[2]. The importance of these aspects is revealed by the fact that there are numerous 10
commercially and non-commercially available E. coli expression vectors that incorporate 11
different backbones, promoters, fusion tags, and cloning procedures. Since sophisticated 12
plasmid constructions are hardly engineered in a routine way with the exclusive use of 13
specific endonuclease restriction sites, restriction enzyme-and ligation-independent cloning 14
strategies of a target gene have become powerful tools [3, 4]. These strategies avoid the use 15
of restriction endonuclease digestion and ligation of polymerase chain reaction products, 16
allowing any gene to be cloned into an expression vector regardless of its sequence [5, 6].17
Conversely, purification of recombinant proteins is accelerated by attachment of 18
affinity tags to the N-or C-terminus of the expressed protein [7-10]. One of the simplest 19
and most widely used tag is the His6-tag which permits affinity purification by immobilized 20
metal-affinity chromatography (IMAC). Despite its relative small size and charge of the 21
His6-tag, it is often useful to remove it for biological and functional studies since it can 22
potentially interfere with the proper functioning of the protein [11]. Removal of the tag 23
from a protein of interest can be accomplished with site-specific proteases, with the most 24
4commonly used being enterokinase (EK), factor Xa, PreScission, tobacco etch virus (TEV), 1
and thrombin. Nevertheless, even with the wide arsenal of expression vectors, tags and tag-2
removal strategies, structural genomics protein production facilities reveal success rates for 3
soluble purified proteins less than 50% [12], which indicates that the choice of protein 4
production strategy largely depends on the target protein [13]. 5
In this scenario, we have previously described two expression vectors, pURI2 and 6
pURI3, which enable parallel cloning of a given target gene for producing recombinant 7
His-tagged proteins [5]. The vectors were constructed using the pT7-7 and pIN-III(lpp
p
-8
5)A3 plasmids as their template. At the N-terminus, the sequences of the His6-tag and the 9
enterokinase cleavage site were introduced in both vectors. They were designed to avoid 10
the restriction enzyme and ligation steps during the cloning, so parallel cloning of the same 11
polymerase chain reaction fragment can be carried out since both vectors shared the same 12
leader sequence. As described elsewhere, we have successfully used these vectors to 13
prepare protein samples that have been subjected to structural analyses by protein 14
crystallography such as catabolic ornithine transcarbamylase from Lactobacillus hilgardii15
[5, 14], p-coumaric acid decarboxylase [15, 16] and a glycosidase [17] from L. plantarum. 16
Moreover, several L. plantarum proteins overproduced by these vectors were biochemically 17
characterized, a p-coumaric acid decarboxylase (PAD) [18], benzyl alcohol dehydrogenase 18
[19], tannin acyl hydrolase [20], and nitroreductase [21], among others.19
To increase the usefulness of pURI vectors and taking into account that the success 20
in a protein production protocol depends on the specific protein, here we report the 21
construction of new vectors from the family of pURI plasmids. These are also designed for 22
an efficient purification of recombinant proteins. The pURI-TEV vectors incorporate a 23
TEV cleavage site, the pURI-Ery vectors have erythromycin as selectable marker, and 24
5finally, pURI-Cter vectors produce a His6-tag in the C-terminus of the recombinant protein 1
(Table 1).2
3
4
Materials and methods 5
6
Strains 7
Escherichia coli DH5αF´[F´/ endA1 hsdR17(rk-mk+) supE44 thi-1 recA1 gyrA(Na1r) 8
relA1 Δ(lacIZYA-argF)U169 deoR (Φ80dlacΔ(lacZ)M15); Promega] was used for all DNA 9
manipulations and for expression in pURI2-derived vectors. E. coli JM109 (DE3) [endA1 10
recA1 gyrA96 hsdR17 supE44 relA1 thiΔ(lacpro)F´(traD36 proAB+ lacIq11
lacZΔM15)λc1857 ind1Sam/nin 5 lacUV5-T7 gene 1; Promega] was used for expression in 12
pURI3-derived vectors. Lactobacillus plantarum CECT 748
T
was purchased from the 13
Spanish Type Culture Collection and Lactobacillus brevis RM 273 was isolated from wine14
[22]. Plasmids pIN-III(lpp
p
-5)A3 [21, 22] and pT7-7 (USB) are expression vectors that 15
allow the overexpression of the desired protein upon induction with isopropyl-β-D-16
thiogalactopyranoside (IPTG). The pUCE191 vector was constructed by cloning the 17
fragment that contains the Ery
R
gene from the pFB9 plasmid into the pUC19 vector [25].18
Plasmid pFB9 is a plasmid originated from a Gram-positive host, Staphylococcus aureus, 19
which was able to replicate and express Ery
R
in a Gram-negative organism, E. coli. The 20
plasmid-encoded Ery
R
gene product  N
6
-dimethylates a specific adenine in 23S ribosomal 21
RNA [26]. E. coli cells carrying pUCE191 could be grown either in erythromycin (200 22
μg/ml) or ampicillin (100 μg/ml). pUCE191 has been used for insertion-duplication 23
6mutagenesis or illegitimate recombination between Gram-positive and Gram-negative 1
species.2
E. coli strains were cultured in Luria-Bertani (LB) medium [27] at 37 ºC and 200 3
rpm. When required, ampicilin or erythromycin was added to the medium at a 4
concentration of 100 or 200 μg·mL-1, respectively. Chromosomal DNA, plasmid 5
purification, and transformation of E. coli were carried out as described elsewhere [27].6
7
8
Construction of pURI2-TEV and pURI3-TEV expression vectors 9
10
The construction of these new expression vectors was carried out by the same 11
procedure used for the pURI2 and pURI3 construction [5] but replacing the sequence 12
encoding the EK site by a TEV site in the forward oligonucleotide primer. The pURI2-TEV 13
vector was constructed from plasmid pIN-III(lpp
p
-5)A3 digested with XbaI and HindIII 14
(Figure 1). The 230 bp insert was amplified by long primers 251 and 245 from L. brevis15
DNA, and digested with the same enzymes. The forward primer 251, from 5´to 3´direction, 16
contained the following: 22 nucleotides that paired the pIN-III(lpp
p
-5)A3 sequence from 17
the unique XbaI recognition site, a His6-tag, the TEV recognition site, and 35 nucleotides 18
pairing the L. brevis sequence (251, 5´-19
ACTCTAGAGGGTATTAATAATGGGGGGTTCTCATCATCATCATCATCATGGTGAA20
AACCTGTATTTCCAGGGCATGCCTGCTACTGCTAATCGCTATCATTTTGGCGG) 21
(the XbaI restriction site is underlined, the sequence coding the TEV recognition site is 22
written in bold, and that coding for the poly-His tag is indicated in italics). The reverse 23
primer, primer 245, is the one used previously for the construction of pURI2 vector [5]. The 24
7amplified fragment was digested with the XbaI and HindIII enzymes, and subsequently 1
ligated to the pIN-III(lpp
p
-5)A3 digested with the same enzymes.2
Expression vector pURI3-TEV was constructed by a similar protocol (Figure 2). 3
Expression vector pT7-7 was digested with NdeI and HindIII restriction enzymes. The L. 4
brevis internal fragment was amplified by long oligonucleotides 252 and 245. 5
Oligonucleotide 252 was identical to primer 251, except that the nucleotides based on the 6
pIN-III(lpp
p
-5)A3 sequence were substituted by nucleotides based on the pT7-7 sequence 7
containing a NdeI restriction site (252, 5´-8
AGATATACATATGGGGGGTTCTCATCATCATCATCATCATGGTGAAAACCTGTAT9
TTCCAGGGCATGCCTGCTACTGCTAATCGCTATCATTTTGGCGG) (the NdeI 10
restriction site is underlined, the TEV recognition site is written in bold, and the His6-tag is 11
indicated in italics). The amplified fragment was digested with NdeI and HindIII enzymes 12
and ligated to the vector pT7-7 digested with the same enzymes.13
Sequences of the pURI2-TEV and pURI3-TEV vectors were verified by restriction 14
analysis and DNA sequencing. 15
16
17
Construction of pURI2-Ery and pURI3-Ery expression vectors 18
19
The construction of these new expression vectors was carried out by the restriction 20
enzyme-and ligation-independent cloning strategy used to clone any gene into pURI 21
vectors [5]. The erythromycin resistance gene, 732 bp, was amplified from the pUCE191 22
vector [25] by Pfu DNA polymerase using the following oligonucleotides, forward 697 23
(5´-CAATAATATTGAAAAAGGAAGAGTatgaacgagaaaaatataaaacaca) and reverse 698 (5´-24
8ATGAGTAAACTTGGTCTGACAGttacttattaaataatttatagctatt) (the nucleotides pairing the 1
expression pURI vector sequence are indicated in italics, and the nucleotides pairing the 2
erythromycin gene sequence are written in lowercase letters; the start and stop codons are 3
indicated in bold). After the amplification, the 732 bp fragment was used to substitute the 4
ampicillin resistance gene present in pURI vectors, by using this fragment as homologous 5
primer pair in a PCR reaction using pURI2 or pURI3 vectors as template. The product of 6
this PCR was digested with DpnI that exclusively restricts methylated DNA. E. coli cells 7
were transformed directly with the digestion product and plated on LB plates containing 8
erythromycin at 200 μg/ml. The construction of the pURI2-Ery and pURI3-Ery vectors was 9
verified by DNA sequencing (Figure 3).10
11
12
Construction of pURI2-Cter and pURI3-Cter expression vectors 13
14
The construction of these pURI vectors containing the His6-tag placed on the C-15
terminus of the recombinant protein was carried out by the strategy used for the 16
construction of pURI2 and pURI3 vectors [5]. The pURI2-Cter vector was constructed 17
from plasmid pIN-III(lpp
p
-5)A3 digested with XbaI and HindIII (Figure 4). The 230 bp 18
insert was amplified from L. brevis DNA by the primers 412 and the long primer 411, and 19
digested with the same enzymes. The forward primer 412, from 5´to 3´direction, contained 20
22 nucleotides that paired the pIN-III(lpp
p
-5)A3 sequence from the unique XbaI recognition 21
site and 22 nucleotides pairing the L. brevis sequence (412, 5´-22
ACTCTAGAGGGTATTAATAATGcctgctactgctaatcgctatc) (the XbaI restriction site is 23
underlined, and the nucleotides pairing the L. brevis sequence are written in lowercase 24
9letters). The reverse long primer, primer 411, contained from 5´to 3´direction, a HindIII 1
restriction site, several stop codons arranged in tandem, a His6-tag, a NotI restriction site, 2
and 27 nucleotides pairing the L. brevis sequence (411 , 5´-3
CCAAGCTTAGTTAGCTATTAATGATGATGATGATGATGTGCGTAGCGGCCGCAGA4
TTCAGTAAAGCCTCGTGTCGCTCG) (the HindIII and NotI restriction sites are 5
underlined, and the poly-His tag is written in italics). The amplified fragment was digested 6
with XbaI and HindIII and ligated to the pIN-III(lpp
p
-5)A3 cut with the same enzymes.7
Vector pURI3-Cter was constructed by the same strategy (Figure 5). The L. brevis8
DNA fragment was amplified by the primer 410 and the long primer 411, which had been 9
explained above. The forward primer 410, from 5´to 3´direction contained an NdeI 10
restriction site followed by 22 nucleotides pairing the L. brevis sequence (410, 5´-11
AGATATACATATGcctgctactgctaatcgctatc) (the NdeI restriction site is underlined, and the 12
nucleotides pairing the L. brevis sequence are written in lowercase letters). The amplified 13
DNA fragment was digested with NdeI and HindIII restriction enzymes, and ligated to the 14
pT7-7 vector digested with the same enzymes. 15
Restriction analysis and DNA sequencing was used to verify the pURI2-Cter and 16
pURI3-Cter sequences.17
18
19
Cloning and expression of the target gene and purification of the encoded protein 20
21
The gene encoding the phenolic acid decarboxylase (PAD) from L. plantarum was 22
cloned in all the pURI vectors to check the efficacy of the new vectors. The aim of the 23
vector family is to allow the use of only few (six) oligonucleotides for the cloning of a 24
10
specific gene in the eight different pURI vectors (Table 2). The cloning of the PAD gene in 1
pURI3 vector has been previously described [15, 18]. The gene coding for the L. plantarum2
PAD was cloned into pURI3 vector by using 274 and 275 oligonucleotides [15, 18], being 3
primer 274 (5´-CATCATGGTGACGATGACGATAAGatgacaaaaacttttaaaacacttg) and 275 4
(5´-AAGCTTAGTTAGCTATTATGCGTAttacttatttaaacgatggtagttt). The same 5
oligonucleotide pair is used to clone into pURI2, pURI2-Ery and pURI3-Ery vectors. To 6
clone into pURI2-TEV and pURI3-TEV vectors, oligonucleotides 413 and 275 were used 7
(primer 413, 5´-GGTGAAAACCTGTATTTCCAGGGCatgacaaaaacttttaaaacacttg). 8
Finally, to clone into pURI2-Cter, the pad gene was amplified by 419 and 420 primer set, 9
and oligonucleotides 421 and 420 were used to clone into pURI3-Cter vector (primer 419, 10
5´-CTGGAACTCTAGAGGGTATTAATAatgacaaaaacttttaaaacacttg; 420, 5´-11
GCTATTAATGATGATGATGATGATGcttatttaaacgatggtagttttg; 421, 5´-12
TAACTTTAAGAAGGAGATATACATatgacaaaaacttttaaaacacttg) (the nucleotides pairing 13
the expression vector sequence are indicated in capital letters and the nucleotides pairing 14
the pad gene sequence are written in lower case; the sequence coding the His6-tag is 15
indicated in italics, and the start and stop codons of the recombinant protein are written in 16
bold). All the PCR amplifications were for 30 cycles with the following conditions: 95 ºC, 17
30s; 55 ºC, 1 min; 72 ºC, 1 min. After amplification, the 0.5 kb PCR products were gel-18
purified and inserted into pURI vectors by using the enzyme restriction-and ligation-free 19
cloning strategy described previously for pURI2 and pURI3 vectors [5]. Briefly, the 20
purified PCR products were used as homologous primer pair in a PCR reaction using the 21
corresponding expression vectors as template. The product of this PCR was digested with 22
DpnI, that exclusively restrict methylated DNA and, later, with NotI, an enzyme that only 23
11
cuts the original copies of pURI vectors. E. coli DH5α cells were transformed directly with 1
the digestion product [5].2
pURI2-derivatives were amplified in the E. coli DH5α or JM109 (DE3) cells, and 3
pURI3-derivatives plasmids in the host JM109 (DE3) E. coli strain. Ten different colonies 4
were selected from E. coli JM109 (DE3) (pURI2—TEV-PAD) to observe cell-to-cell 5
variation on protein production. Cells carrying a recombinant plasmid were grown at 37 ºC 6
in Luria-Bertani media containing ampicillin (100 μg/mL final concentration) or 7
erythromycin (200 μg/mL final concentration), when required, and induced by adding IPTG 8
(0.4 mM final concentration) when culture OD600nm was 0.5. After induction, the cells were 9
grown at 22 ºC during 20 h and collected by centrifugation. Crude extracts were prepared 10
by French Press lysis (three cycles at 1100 psi) of cell suspensions obtained by suspending 11
the frozen cell paste with 20 mM Tris-HCl, pH 8.0, 100mM NaCl. The insoluble fraction of 12
the lysate was removed by centrifugation at 47000g for 30 min at 4 ºC. The relative 13
proportions of soluble and insoluble material that were expressed for each of the constructs 14
were determined. Samples of both the soluble and insoluble fractions were analyzed by 15
SDS-PAGE. The presence of PAD protein on the gels was quantified by using the 16
ChemiDoc XRS+ Imagin System (Bio-Rad) using pURI2/pURI3 as controls.17
The soluble cell homogenate, obtained by French Press lysis of the E. coli cells 18
containing the pad gene cloned on each one of the pURI vectors, was then applied to a His-19
Trap-FF crude chelating affinity column (Amersham Biosciences, Uppsala, Sweden) using 20
an ÄKTA-Prime system (Amersham Pharmacia Biotech). The column was equilibrated 21
with 20 mM Tris-HCl, pH 8.0, 100 mM NaCl containing 10 mM imidazole, to improve the 22
interaction specificity in the affinity chromatography step. The bound enzyme was eluted 23
by applying a continuous gradient of imidazole concentration, from 20 mM Tris-HCl, pH 24
12
8.0, 100 mM NaCl containing 10 mM imidazole to 20 mM Tris-HCl, pH 8.0, 100 mM 1
NaCl containing 500 mM imidazole. Fractions containing the eluted PAD were pooled and 2
the protein was then dialyzed against 20 mM Tris-HCl, pH 8.0, 100 mM NaCl. The 3
concentration of PAD was estimated using the Bio-Rad protein assay. In the fused TEV-4
PAD protein produced by the pURI3-TEV vector, the PAD protein (5 mg/mL) was 5
incubated with one unit of recombinant TEV at 4 ºC for 20 h. After digestion, the sample 6
was run on a sodium dodecyl sulfate (SDS) gel to check the cleavage.7
PAD activity was determined by following the decarboxylation of p-coumaric acid 8
into vinyl phenol according to the method previously described [18]. Briefly, the standard 9
reaction was performed by adding 200 μg/mL of protein from the cell-free extract or adding 10
3 μg/mL of purified PAD enzyme into a solution containing 1mM p-coumaric acid in 25 11
mM phosphate buffer (pH 6.5). The reaction was incubated at 37 ºC during 1h, for cell 12
extracts, or 20 min for pure PAD protein. The reaction products were extracted twice with 13
ethyl acetate and analyzed by HPLC.14
15
16
Results and Discussion 17
18
19
Characterization of the pURI Family Expression Vectors 20
21
One of the main conclusions derived from structural genomics protein production 22
facilities is that the success rates for soluble purified proteins largely depends on the target 23
protein itself [13] and therefore the choice of the adequate system for production of a 24
13
specific protein is mainly based on a trial-and-error approach. With the aim of providing a 1
new tool for the production of recombinant proteins, we previously created two expression 2
vectors pUIR2 and pURI3 based on the pIN-III(lpp
p
-5)A3 and pT7-7 plasmids, 3
respectively, which share the same cloning procedure and protein purification setup [5].4
These vectors were specifically designed to avoid the restriction enzyme and ligation steps 5
during the cloning, and included an N-terminal His6-tag which allows convenient affinity 6
purification of the target protein from crude cell extracts and also an enterokinase cleavage 7
site that leaves no extra residues in the protein upon tag removal. In addition, a unique NotI 8
site was introduced to facilitate the selection of the adequate recombinant plasmid. 9
Moreover, pURI2 and pUIR3 vectors included a 230 bp L. brevis noncoding intergenic 10
region to facilitate the integration of long DNA fragments. Parallel cloning of the same 11
PCR fragment can be carried out since both vectors shared the same leader sequence. These 12
vectors were successfully used to hyperproduce several proteins from lactic acid bacteria13
[5, 14-21].14
To increase the usefulness of the pURI vectors we decided to expand its versatility 15
by creating a vector family, which combines different protease recognition sites, different 16
antibiotic selectable markers, and also different placement of the His6-tag (Table 1). Two 17
endoproteases were considered for tag removal namely, enterokinase and TEV. 18
Enterokinase specifically recognizes a five-amino acid polypeptide (DDDKX) and cleaves 19
at the carboxyl site of the lysine side chain. However, sporadic cleavage at other residues 20
was observed to occur at low levels, depending on the conformation of the protein [28].21
Conversely, TEV protease is also an ideal tool for removing tags from fusion proteins due 22
to high specificity; the optimal recognition sequence is ENLYFQG, with the cleavage 23
occurring between the conserved glutamine and glycine residues. TEV protease is attractive 24
14
because it can be expressed and purified in the lab (making it cost-effective), and leaves 1
only one glycine residue at the N-terminus of the protein upon cleavage [30]. The optimal 2
temperature for cleavage is 34 ºC; however, the enzyme can also be used at temperatures as 3
low as 4 ºC and is active under a wide range of conditions and in the presence of various 4
protease inhibitors [31-33]. To construct pURI2-TEV and pURI3-TEV vectors, long 5
oligonucleotides pairing the L. brevis sequence and containing all the required elements 6
(His6-tag, TEV recognition site) were used as described in Materials and Methods. 7
Expression vector pURI2-TEV was constructed by using 251 and 245 primers, and vector 8
pURI3-TEV by using 252 and 245 primers. Both expression vectors shared a common 316 9
bp fragment from the ATG start codon upstream from the His6-tag coding sequence to the 10
HindIII restriction site (Figure 1 and 2). The common DNA fragment is identical to the 310 11
pb fragment included in the pURI2/pURI3 vectors but replacing the enterokinase 12
recognition site by the TEV protease site (Table 1).13
The selective markers ―amp‖ (ampicillin resistance, also abbreviated Ap or bla for 14
β-lactamase) and ―Ery‖ (erythromycin resistance, also abbreviated em) have been widely 15
used. While ampicillin resistance is commonly used for selection in a variety of cloning 16
vectors, erythromycin resistance may be preferable under certain specific conditions, and 17
when subcloning target genes from other ampicillin-resistant vectors. The erythromycin 18
resistance gene from pUCE191 was amplified with oligonucleotides 697 and 698. The 732 19
bp amplified fragment was used to replace the ampicillin resistance gene, 858 bp, found in 20
the pURI2 and pURI3 vectors. The 732 erythomycin fragment was introduced into pURI2 21
and pURI3 vectors by the restriction enzyme-and ligation-independent cloning strategy 22
used to clone any gene into the pURI vector family. The new vectors, pURI2-Ery and 23
pURI3-Ery will permit the production of recombinant proteins with the same characteristics 24
15
as those produced by the formers pURI2 and pURI3 vectors (e.g., initial methionine 1
followed by a three amino acid spacer, a six histidine affinity tag, a spacer glycine residue, 2
and the five amino acid enterokinase recognition site) (Figure 3, Table 1). The direction of 3
the transcription of the drug resistance gene also needs to be considered. In all pURI 4
vectors, the resistance genes Amp and Ery are in opposite orientation from the lpp
p
-5 5
(pURI2) or Ø10 (pURI3) promoters, so induction of these promoters should not result in an 6
increase in antibiotic resistance gene product. In order to increase the versatility of the 7
pURI vectors, in addition to ampicillin and erythromycin resistance, kanamycin resistance 8
pURI-derivatives have been also constructed by using the same strategy (data not shown)9
Poly-histidine affinity tags are placed on either the N- or the C-terminus of 10
recombinant proteins, although the optimal location does vary depending on the folding and 11
biochemical characteristics of the target protein. In principle, it cannot be excluded that the 12
affinity tag may interfere with protein activity, although the relative small size and charge 13
of the His6-tag ensure that protein activity is rarely affected. Halliwell et al. (2001) [34]14
fused a poly-His tag to either the N-or the C-terminus of L-lactate dehydrogenase of 15
Bacillus stearothermophilus, and found that the C-terminally tagged enzyme displayed 16
lower activity compared both to the wild-type and to the N-terminally tagged variant, 17
probably due to a misfolding of the enzyme. In enzymes possessing a three-dimensional 18
structure available, it is necessary to check whether the N-terminus or the C-terminus are 19
noninteracting with the substrate and cofactor-binding sites. In order to offer production of 20
recombinant C-terminally tagged proteins, pURI2-Cter and pURI3-Cter expression vectors 21
were created (Figure 4 and 5, Table 1). To construct pURI2-Cter vector oligonucleotides 22
412 and 411 were used; similarly, pURI3-Cter was constructed by using 410 and 411 23
oligonucleotides. Both expression vectors shared a common 280 bp fragment from the 24
16
ATG start codon to the HindIII restriction site downstream from the His6-tag coding 1
sequence. The common DNA fragment encodes for the following: a N-terminal methionine 2
followed by the 230 bp noncoding intergenic L. brevis sequence, a rare-cut NotI restriction 3
site, a six histidine affinity tag, four stop codons arranged in tandem, and finally, a HindIII 4
restriction site (Figure 4 and 5).5
As indicated in Table 2, by the use of only six nucleotide primers, a gene can be 6
expressed in eight different expression vectors by using a similar restriction enzyme-and 7
ligation-independent cloning strategy for producing a recombinant His-fusion protein. The 8
designed pURI vectors allows to use different promoters (lpp and T7 RNA polymerase 9
promoters), different protease cleavage sites (enterokinase and TEV protease), different 10
selective markers (ampicillin and erythromycin) and different poly-His tag placements (N-11
or C-terminus) for the production of a protein of interest (Table 1).12
13
14
Cloning and expression of the gene encoding the L. plantarum PAD protein and 15
purification of the recombinant protein16
17
PAD enzymes are biotechnologically relevant enzymes that catalyze the conversion 18
of ferulic or p-coumaric acids into the corresponding volatile derivatives 4-vinyl guaiacol 19
(3-methoxy-4-hydroxystyrene) or 4-vinyl phenol (4-hydroxystyrene), considered as 20
precursors of vanillin (4-hydroxy-3-methoxybenzaldehyde) production. Vanillin is the most 21
commonly used flavour in foods, beverages, perfumes or pharmaceuticals. Vinyl guaiacol 22
is priced around 40 times more than ferulic acid, and it can be biotransformed further to 23
acetovanillone, ethylguaiacol, and vanillin [35]. As a styrene-type molecule, vinyl guaiacol 24
17
can be polymerized; the resultant oligomer [poly(3-methoxy-4-hydroxystyrene)] was found 1
to be easily biodegradable [36]. In addition, the 4-vinyl guaiacol or 4-vinyl phenol, 2
produced by the activity of PAD enzymes on hidroxycinnamic acids, are considered to be 3
food additives and are approved as flavouring agents by regulatory agencies [37]. 4
By using the pURI3 plasmid, we have overproduced, crystallized and solved the 5
three dimensional structure of PAD from L. plantarum [15, 16, 18]. The procedure 6
employed for cloning the pad gene into pURI3 vector can also be used to clone into each 7
one of the vectors from the pURI family. Briefly, PCR products of the gene of interest need 8
to be generated with specific overhangs that are complementary to the integration site 9
sequence of the vectors. The nucleotide sequence of the gene encoding the target protein is 10
amplified by PCR using specific oligonucleotides (Table 2) and Pfu DNA polymerase. 11
Generally, the sequence of forward primers include the sequence showed in Table 2, where 12
the last three nucleotides encode the first methionine residue of the target protein, followed 13
by nucleotides pairing the sequence from the second amino acid residue of the target 14
protein. Similarly, reverse primers include the sequence showed in Table 2, followed by 15
nucleotides pairing the sequence up to the stop codon of the target protein; however, to 16
clone in the pURI-Cter vectors, the protein stop codon is not included into the primer 17
sequence, as it is included after the His6-tag (Table 2). The PCR fragment is added as 18
megaprimer to the methylated recipient template plasmid. After the denaturation step, the 19
homologous parts of the PCR fragment hybridize to the defined integration site and these 20
fragments are elongated in vitro by the Pfu DNA polymerase. The elongated and modified 21
strands are not methylated. When PCR is finished, they are treated with the DpnI enzyme, 22
which exclusively restricts methylated DNA, removing the methylated templates. An 23
18
additional screening tool herein used is a NotI digestion of the template plasmid, which can 1
only be used if the target gene sequence lacks such restriction site.2
The pURI2-derived expression vectors could be used in a single strain of E. coli in 3
all steps from plasmid construction to the expression of the target gene. However, in 4
pURI3-derived vectors, the plasmid needs to be cloned into any cloning E. coli strain, and 5
for expression, into E. coli DE3 cells. Therefore, E. coli DE3 cells could be used for gene 6
expression in all the designed pURI vectors. The gene coding for the PAD protein was 7
expressed into all the pURI family vectors by IPTG induction (0.4 mM final concentration). 8
Following expression, the cell densities of the cultures were normalized to an OD600nm of 9
5.0 prior to lysis, which allowed for a uniform number of cells for all the samples. The 10
cultures were then lysed and centrifuged to sediment insoluble cell debris. The six new 11
pURI vectors were checked for PAD production, and the relative proportions of soluble and 12
insoluble expression of PAD was assessed. Two important aspects can be deduced from 13
Figure 6A: firstly, soluble PAD is detected in all the cultures and secondly, the protein 14
production levels were dependent on the pURI vector used. Taking into account the size of 15
the His6-tag, the expected size of the hyperproduced protein is 21.8 kDa. An obvious 16
soluble protein production from crude extracts was obtained by pURI-Cter vectors, 17
especially by pURI3-Cter. Even though no apparent PAD hyperproduction was achieved by 18
using other pURI vectors (e.g., pURI2-TEV) (Figure 6 and 7), PAD proteins were purified 19
from all the extracts by IMAC (data not shown). After purification, the final protein 20
production yield varied from 1.29 mg/l (pURI2-TEV) to 13.84 mg/l (pURI3-Cter). As 21
shown in Figure 6B, PAD was largely expressed as insoluble material with in Cter derived 22
vectors (pURI2-Cter and pURI3-Cter), although soluble protein was largely obtained in 23
both vectors. In contrast, pURI2 and pURI3 vectors rendered the highest proportion of 24
19
soluble PAD protein, which produced PAD in the proportions of 4:1 and 6:1 1
(soluble:insoluble), respectively (Figures 6 and 7). Additionally, Figure 7 indicates that 2
both pURI-TEV vectors produced the highest yield of the insoluble form of the protein. In 3
order to check cell-to-cell variation on protein production, ten different E. coli JM109 4
(DE3) cells transformed with pURI2-TEV-PAD vector were selected. Soluble cell-extracts 5
from cultures of these colonies revealed that PAD production was similar in all of them, 6
sharing a common expression profile (Figure 9). This result indicated that the different 7
protein yield observed among the pURI vectors are due to vector borne enhancement and 8
not to clonal variances.9
As E. coli DE3 cells could be used for gene expression in all the pURI vectors, these 10
cells were used to produce PAD by using each one of the eight designed vectors (Figure 11
10). The protein production profile showed by the different pURI2 vectors on E. coli 12
JM109 (DE3) cells was similar to that showed on E. coli DH5α. Vector pURI2-TEV-PAD13
yielded the lowest soluble protein production, whereas pURI2-Cter-PAD produced the 14
highest PAD yield (48.45 mg/l), more than three times higher than on DH5α cells (Figure 15
6). Therefore, the choice of the E .coli cells used as a host had a relevant role in protein 16
production [1].17
 Therefore, this study illustrates the usefulness of the new family of pURI 18
expression vectors when considered as tool for the parallel cloning and expression of a 19
recombinant protein whose production yield may vary significantly on the vector used. 20
The activity of the purified His6-tagged PAD proteins was determined by measuring 21
the decarboxylation of p-coumaric acid into vinyl phenol. When cell extracts were assayed 22
the reaction was fully decarboxylated to vinyl phenol, except by pURI2-Ery and pURI2-23
TEV extracts which transformed 90% or only a 20% of the substrate. Both cell extracts 24
20
contained the lowest PAD protein in the soluble form (Figure 7A). However, when the 1
different purified PAD proteins were compared, all showed the same specific activity (data 2
not shown), indicating that the location of the His6-tag as well as the protease cleavage site 3
did not affect catalytic activity. 4
The proper function of the TEV cleavage site was demonstrated on the recombinant 5
PAD protein produced in the pURI3-TEV vector. The fused PAD protein was purified, 6
dialyzed, and digested with TEV protease at 4 ºC. Figure 8 showed the digested PAD 7
sample, it could be observed that the suppression of the leader sequence containing the 8
affinity tag (17 amino acid residues) produces an expected reduction in the protein size, 9
from a predicted 23 kDa (196 amino acid fused protein) to a 21 kDa cleaved protein (179 10
amino acids). The functionality of the EK cleavage site on pURI vectors was previously 11
demonstrated [5].12
In summary, since the production yield of soluble recombinant protein largely 13
depends on the target protein itself, and considering that one of the major bottlenecks in the 14
structural studies is the large-scale production of pure and active proteins, we herein 15
provide a new family of expression vectors that may allow the overproduction and further 16
purification of soluble recombinant proteins. These vectors are based on the previously 17
described and successfully used pURI2 and pURI3 plasmids. The usefulness of the pURI 18
vectors was increased by the presence of different protease recognition sites to remove the 19
His6-tag, different antibiotic selectable marker, and different placement of the affinity tag. 20
By the use of only six nucleotide primers a gene can be expressed in eight different 21
expression vectors with a similar restriction enzyme-and ligation-independent cloning 22
strategy. The target protein chosen for the validation of the pURI vector family has 23
evidenced the different protein production obtained by each one of the pURI vectors, and 24
21
also pointed out the difficulty to decide empirically which system is the best for a 1
heterologous protein production as it depends often on the target protein itself. Therefore 2
the availability of a set of different, but related, expression vectors for parallel cloning 3
confers great advantages for the production of a protein of interest.4
5
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Figure captions 12
13
Fig. 1. (A) Schematic representation of the expression vector pURI2-TEV (7791 bp). (B) 14
Sequence of pURI2-TEV containing the leader sequence encoding region. The expression 15
leader sequence consists of a N-terminal methionine residue followed by a three amino acid 16
spacer, a six histidine affinity tag, a spacer glycine residue, and the seven amino acid TEV 17
recognition site, ENLYFQG, followed by an initial protein methionine. The expression 18
leader sequences are under the control of the lpp
p
-5 and lac
PO
promoters. The TG motif 19
typical of extended -10 boxes is also indicated. Cleavage of expressed protein by TEV 20
protease occurs between the glutamine and glycine residues (QG). Restriction sites are 21
indicated and underlined in the nucleotide sequence: X, XbaI, N, NotI, H, HindIII, and B, 22
BamHI. Tandem stop codons are indicated by asterisks.23
24
27
Fig. 2. (A) Schematic representation of the expression vector pURI3-TEV (2696 bp). (B) 1
Sequence of pURI3-TEV containing the leader sequence encoding region. The expression 2
leader sequence consists of a N-terminal methionine residue followed by a three amino acid 3
spacer, a six histidine affinity tag, a spacer glycine residue, and the seven amino acid TEV 4
recognition site, ENLYFQG, followed by an initial protein methionine. The expression 5
leader sequences are under the control of the T7 polymerase Ø promoter. Cleavage of 6
expressed protein by TEV protease occurs between the glutamine and glycine residues 7
(QG). Restriction sites are indicated and underlined in the nucleotide sequence: Nd, NdeI, 8
N, NotI, H, HindIII, and C, ClaI. Tandem stop codons are indicated by asterisks.9
10
11
Fig. 3. Schematic representation of the expression vectors pURI2-Ery (7659 bp) (A) and 12
pURI3-Ery (2564 bp) (B). The expression leader sequences are the sequences present on 13
pURI2 and pURI3 vectors, respectively [5].14
15
16
Fig. 4. (A) Schematic representation of the expression vector pURI2-Cter (7755 bp). (B)17
Sequence of the pURI2-Cter sequence showing the C-terminus His6-tag followed by four 18
stop codons arranged in tandem. The expression leader sequence is under the control of the 19
lpp
p
-5 and lac
PO
promoters. Restriction sites are indicated and underlined in the nucleotide 20
sequence: X, XbaI, N, NotI, H, HindIII, and B, BamHI. Tandem stop codons are indicated 21
by asterisks.22
23
24
28
Fig. 5. (A) Schematic representation of the expression vector pURI3-Cter (2642 bp). (B) 1
Sequence of the pURI3-Cter sequence showing the C-terminus His6-tag followed by four 2
stop codons arranged in tandem. The expression leader sequence is under the control of the 3
T7 polymerase Ø promoter in pURI3-Cter. Restriction sites are indicated and underlined in 4
the nucleotide sequence: Nd, NdeI, N, NotI, H, HindIII, and C, ClaI. Tandem stop codons 5
are indicated by asterisks.6
7
8
Fig. 6. Expression of the pad gene encoding the PAD protein from L. plantarum cloned 9
into the new pURI expression vectors. SDS-PAGE analysis of soluble (A) and insoluble 10
(B) cell extract fractions from IPTG-induced cultures, respectively. Lane 1, E. coli DH5α 11
(pURI2); lane 2, E. coli DH5α (pURI2-PAD); lane 3, E. coli DH5α (pURI2-TEV-PAD); 12
lane 4, E. coli DH5α (pURI2-Ery-PAD); lane 5, E. coli DH5α (pURI2-Cter-PAD); lane 6, 13
E. coli JM109 (DE3) (pURI3); lane 7, E. coli JM109 (DE3) (pURI3-PAD); lane 8, E. coli14
JM109 (DE3) (pURI3-TEV-PAD); lane 9, E. coli JM109 (DE3) (pURI3-Ery-PAD); lane 15
10, E. coli JM109 (DE3) (pURI3-Cter-PAD). The positions of molecular mass markers 16
(Bio-Rad) are indicated on the left. The position of the PAD protein is indicated by an 17
arrow. The expected sizes of the fused PAD proteins are 22.9 kDa when produced in pURI-18
and pURI-Ery vector, 23.0 kDa when produced in pURI-TEV vectors, and 21.8 kDa when 19
produced in pURI-Cter vectors. 20
21
Fig. 7. Relative proportion of soluble (A) or insoluble (B) L. plantarum PAD protein 22
produced by the different pURI expression vectors: pURI2-PAD (2), pURI2-TEV-PAD (3), 23
pURI2-Ery-PAD (4), pURI2-Cter-PAD (5), pURI3-PAD (7), pURI3-TEV-PAD (8), 24
29
pURI3-Ery-PAD (9), pURI3-Cter-PAD (10). The PAD protein was quantified from the 1
SDS-PAGE gels by using the ChemiDoc XRS+ Imagin System (Bio-Rad). pURI2 (1) and 2
pURI3 (6) vectors were used as controls for the quantification.3
4
Fig. 8.  Cleavage of the L. plantarum PAD protein by TEV protease. PAD was purified 5
from pURI3-TEV-PAD extracts on a His-Trapp-FF crude chelating affinity column, eluted 6
with buffer containing 70 mM imidazole, dialyzed overnight into 20 mM Tris-HCl, pH 8.0 7
buffer free of imidazole, and incubated with TEV protease at 4 ºC. Lane 1, untreated PAD 8
protein (23.0 kDa); and lane 2, PAD protein after 20 h incubation (21.0 kDa). Broad-range 9
molecular weight markers (Bio-Rad) are run on the left and some positions are indicated.10
11
Fig. 9. Production of L. plantarum PAD into ten different colonies of E.coli JM109 (DE3) 12
harbouring pURI2-TEV-PAD plasmid. SDS-PAGE analysis of soluble cell extracts from 13
IPTG-induced cultures. Lane 1 to 10, colony 1 to 10.The positions of molecular mass 14
markers (Bio-Rad) are indicated on the left. The position of the PAD protein is indicated by 15
an arrow. 16
17
Fig. 10. Expression of the pad gene encoding the PAD protein from L. plantarum cloned 18
into the pURI expression vectors by using E. coli JM109 (DE3) cells. SDS-PAGE analysis 19
of soluble cell extracts from IPTG-induced cultures. Lane 1, pURI2; lane 2, pURI2-PAD; 20
lane 3, pURI2-TEV-PAD; lane 4, pURI2-Ery-PAD; lane 5, pURI2-Cter-PAD; lane 6, 21
pURI3; lane 7, pURI3-PAD; lane 8, pURI3-TEV-PAD; lane 9, pURI3-Ery-PAD; lane 10, 22
pURI3-Cter-PAD. The positions of molecular mass markers (Bio-Rad) are indicated on the 23
left. The position of the PAD protein is indicated by an arrow. 24
Table 1 
Table 1. Relevant properties of pURI vector family 
Vector Size 
(kb)
E .coli host Promoter His
Tag
Protease 
site
Antibiotic 
resistance
pURI2 7.8 DH5α, DH10B lppP-5 N-ter EK Amp
pURI2-TEV 7.8 DH5α, DH10B lppP-5 N-ter TEV Amp
pURI2-Ery 7.7 DH5α, DH10B lppP-5 N-ter EK Ery
pURI2-Cter 7.8 DH5α, DH10B lppP-5 C-ter EK Amp
pURI3 2.7 BL21(DE3), JM109 (DE3) Ø10 N-ter EK Amp
pURI3-TEV 2.7 BL21(DE3), JM109 (DE3) Ø10 N-ter TEV Amp
pURI3-Ery 2.6 BL21(DE3), JM109 (DE3) Ø10 N-ter EK Ery
pURI3-Cter 2.7 BL21(DE3), JM109 (DE3) Ø10 C-ter EK Amp
Table 1
Table 2 
Table 2. Oligonucleotides used for cloning into the pURI vector family
Oligonucleotide (5´-3´)
a
pURI2 pURI2-TEV pURI2-Ery pURI2-Cter pURI3 pURI3-TEV pURI3-Ery pURI3-Cter
CATCATGGTGACGATGACGATAAGatg--- forward forward forward forward
GGTGAAAACCTGTATTTCCAGGGCatg--- forward forward
CTGGAACTCTAGAGGGTATTAATAatg--- forward
TAACTTTAAGAAGGAGATATACATatg--- forward
AAGCTTAGTTAGCTATTATGCGTAtta--- reverse reverse reverse reverse reverse reverse
GCTATTAATGATGATGATGATGATG--- reverse reverse
a 
Only the sequence pairing the vector is indicated in the oligonucleotide. The start and stop condons are indicated in bold. The sequence coding 
for the poly-His tag is written in italics. 
Table 2
Figure 1 
A 
B 
SspI lpp promoter
AATATTGACAACATAAAAAACTTTGTGTTATACTTGTAACGCTACATGGAGATTAACTCAATCTAGCTAG 
      -35                     -10 
lac promoter-operator 
AGAGGCTTTACACTTTATGCTTCCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACA 
  -35                     -10 
XbaI RBS
GGAAACAGCTATGACCATGATTACGGATTCACTGGAACTCTAGAGGGTATTAATAATGGGGGGTTCTCAT
                                                        M  G  G  S  H 
His tag      TEV recognition site 
CATCATCATCATCATGGTGAAAACCTGTATTTCCAGGGCATGCCTGCTACTGCTAATCGCTATCATTTTG 
 H  H  H  H  H  G  E  N  L  Y  F  Q  G  M 
GCGGGACACCTGGCATCAGCCCCGCTAACCCTGCGGCCCAAAATCGGGTATACTGAACCTAACTCTTAGT 
AGAAAGTAGGTCAGCGTCATTGGCAAATTACATCAAGGAAATTCGCGAACTCGTCGGTCACAAACCCATC 
NotI 
ATTCTTAACGCTTCTGGTGGTCTGGTGACCAACGAGCGACACGAGGCTTTACTGAATCTGCGGCCGCTAC 
HindIII  BamHI 
GCATAATAGCTAACTAAGCTTGGATCCGGCTGAGCAACGACGTGAACGCAA 
    *  *   *   * 
lppP-5 lacPO ATG ATGHis EK
X N H B
LacI      ApR
pURI2
(7.8 kb)
TEV
pURI2-TEV
Figure 1
Figure 2 
A
B 
                      T7 promoter 
GATAGACTTCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGT 
RBS NdeI               His tag      TEV recognition  
TTAACTTTAAGAAGGAGATATACATATGGGGGGTTCTCATCATCATCATCATCATGGTGAAAACCTGTAT 
                          M  G  G  S  H  H  H  H  H  H  G  E  N  L  Y   
 site 
TTCCAGGGCATGCCTGCTACTGCTAATCGCTATCATTTTGGCGGGACACCTGGCATCAGCCCCGCTAACC 
 F  Q  G  M 
CTGCGGCCCAAAATCGGGTATACTGAACCTAACTCTTAGTAGAAAGTAGGTCAGCGTCATTGGCAAATTA 
CATCAAGGAAATTCGCGAACTCGTCGGTCACAAACCCATCATTCTTAACGCTTCTGGTGGTCTGGTGACC 
NotI                   HindIII  ClaI 
AACGAGCGACACGAGGCTTTACTGAATCTGCGGCCGCTACGCATAATAGCTAACTAAGCTTATCGATGAT 
                                            *  *   *   * 
AAGCTGTCAAACATGAGAATT 
Ø10 ATG ATGHis EK
Nd N H
ApR
pURI3
(2.7 kb)
C
TEV
pURI3-TEV
Figure 2
Figure 3 
A 
B 
Ø10 ATG ATGHis EK
Nd N H
EryR
pU R I3- E ry
(2.6 kb)
C
lppP-5 lacPO ATG ATGHis EK
X N H B
LacIEryR
pU R I2- E ry
(7.7 kb)
Figure 3
Figure 4 
A 
B
SspI lpp promoter
AATATTGACAACATAAAAAACTTTGTGTTATACTTGTAACGCTACATGGAGATTAACTCAATCTAGCTAG 
      -35                     -10 
lac promoter-operator 
AGAGGCTTTACACTTTATGCTTCCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACA 
  -35                     -10 
XbaI RBS
GGAAACAGCTATGACCATGATTACGGATTCACTGGAACTCTAGAGGGTATTAATAATGCCTGCTACTGCT 
                                                        M 
AATCGCTATCATTTTGGCGGGACACCTGGCATCAGCCCCGCTAACCCTGCGGCCCAAAATCGGGTATACT 
GAACCTAACTCTTAGTAGAAAGTAGGTCAGCGTCATTGGCAAATTACATCAAGGAAATTCGCGAACTCGT 
CGGTCACAAACCCATCATTCTTAACGCTTCTGGTGGTCTGGTGACCAACGAGCGACACGAGGCTTTACTG 
NotI             His tag                 HindIII  BamHI
AATCTGCGGCCGCTACGCACATCATCATCATCATCATTAATAGCTAACTAAGCTTGGATCCGGCTGAGCA 
H  H  H  H  H  H  *  *   *   *
ACGACGTGAACGCAA 
lppP-5 lacPO
X H B
LacI      ApR
pURI2
(7.8 kb)
ATG His
N
pURI2-Cter
Figure 4
Figure 5 
A 
B 
                      T7 promoter 
GATAGACTTCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGT 
RBS       NdeI              
TTAACTTTAAGAAGGAGATATACATATGCCTGCTACTGCTAATCGCTATCATTTTGGCGGGACACCTGGC 
                          M 
ATCAGCCCCGCTAACCCTGCGGCCCAAAATCGGGTATACTGAACCTAACTCTTAGTAGAAAGTAGGTCAG 
CGTCATTGGCAAATTACATCAAGGAAATTCGCGAACTCGTCGGTCACAAACCCATCATTCTTAACGCTTC 
NotI           His tag
TGGTGGTCTGGTGACCAACGAGCGACACGAGGCTTTACTGAATCTGCGGCCGCTACGCACATCATCATCA
                                                            H  H  H  H   
HindIII  ClaI 
TCATCATTAATAGCTAACTAAGCTTATCGATGATAAGCTGTCAAACATGAGAATT       
  H  H  *  *   *   * 
Ø10
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